Expert Insights into the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia - Episode 1

Faculty Introductions

, ,

Panelist introductions by Gregory Roloff, MD from the University of Chicago Comprehensive Cancer Center, Chicago, Illinois; Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, New York; and Bijal Shah, MD, from the Moffitt Cancer Center, Tampa, Florida.

Now Viewing
EP. 1: Faculty Introductions
EP. 2: Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL
EP. 3: Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL
EP. 4: Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial
EP. 5: Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease
EP. 6: Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion
EP. 7: Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)
EP. 8: Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy
EP. 9: Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
EP. 10: Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

Related Content:

Expert Insights into the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic LeukemiaHematologic Oncology
FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies
OncLive’s October Roundup of Key FDA Approvals in Oncology